Icon(DE:IJF)
€170.15-9.65 (-5.37%)
DE:IJF
Icon stock drug pipeline
€170.15
At close:-9.65 (-5.37%)
Icon (IJF) Drug Pipeline
3 Followers
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Icon Plc (DE:IJF) have in its pipeline
Icon DE:IJF is currently developing the following drugs: Camizestrant, Ribociclib, Azd9833, Anifrolumab, Jynneos, Mva-Bn, Petrelintide, Kedrion Ivig 10%, Belimumab, Mtx-463, H1 Influenza Antigen, Prx-102 1 Mg/Kg Every Two Weeks, Jcxh-105, Active Control, Jcxh-221, Altb-268, Sp-420, Prx-102 1 Mg/Kg Every 2 Weeks, Prx-102 2 Mg/Kg Every 4 Weeks, Mt1980, Bxq-350, Fp-101, Mrx0029, Mrx0005, Vudalimab, Imgatuzumab, Leo 153339, Mb-Cart2019.1, R-Gemox Or Br Plus Polatuzumab Vedotin, Autologous Genetically Modified Adp-A2m4cd8 Cells, Mrg-001, Pembrolizumab, Pemetrexed, Tomivosertib, Xmab18087, Xmab18087 ± Pembrolizumab, Allob, Vortioxetine, Probiotic, Autologous Genetically Modified Adp-A2m4cd8 Cells Alone Or In Combination With Nivolumab Every Four Weeks Or Pembrolizumab Every 6 Weeks, Mb-Cart2019.1 Dose Level 1, Mb-Cart2019.1 Dose Level 2, Xanamem, Xmab23104, Yervoy, Rjx, Xmab20717, Sernova Cell Pouch, Xmab18087, Pegfilgrastim, Plinabulin, Saline, Vas203, Ecn-Suspension. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

